학술논문
Live-attenuated Mycobacterium tuberculosisvaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial
Document Type
Article
Author
Tameris, Michele; Mearns, Helen; Penn-Nicholson, Adam; Gregg, Yolande; Bilek, Nicole; Mabwe, Simbarashe; Geldenhuys, Hennie; Shenje, Justin; Luabeya, Angelique Kany Kany; Murillo, Ingrid; Doce, Juana; Aguilo, Nacho; Marinova, Dessislava; Puentes, Eugenia; Rodríguez, Esteban; Gonzalo-Asensio, Jesús; Fritzell, Bernard; Thole, Jelle; Martin, Carlos; Scriba, Thomas J; Hatherill, Mark; Africa, Hadn; Arendsen, Denis; Botes, Natasja; Cloete, Yolundi; De Kock, Marwou; Erasmus, Margaret; Jack, Lungisa; Kafaar, Fazlin; Kalepu, Xoliswa; Khomba, Nondumiso Gloria; Kruger, Sandra; Leopeng, Thelma; Makhethe, Lebohang; Mouton, Angelique; Mulenga, Humphrey; Musvosvi, Munyaradzi; Noble, Julia; Opperman, Fajwa; Reid, Tim; Rossouw, Susan; Schreuder, Constance; Smit, Erica; Steyn, Marcia; Tyambethu, Petrus; Van Rooyen, Elma; Veldsman, Ashley
Source
The Lancet Respiratory Medicine; September 2019, Vol. 7 Issue: 9 p757-770, 14p
Subject
Language
ISSN
22132600; 22132619
Abstract
Infants are a key target population for new tuberculosis vaccines. We assessed the safety and immunogenicity of the live-attenuated Mycobacterium tuberculosisvaccine candidate MTBVAC in adults and infants in a region where transmission of tuberculosis is very high.